"The Company Plans A Documentary Featuring Dr. Lynnice Wedewer, Ph.D., And Other Cancer Patients Being Treated with Medical Cannabis"
2011-06-29 from [https://www.cannabisscience.com/index.php/news-media/news-archive/201-cannabis-science-announces-critical-cancer-patient-dr-lynnice-wedewer-ph-d-cured-seven-times-by-medical-cannabis]:
COLORADO SPRINGS, Colo.--
Cannabis Science Inc. (NASD OTCBB: CBIS) a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that it has been contacted by Lynnice Wedewer, Ph.D. who is a 34 year multiple cancer patient survivor who has been cured of 7 of her 8 cancers in a major part because of medical cannabis. Dr. Wedewer wishes to share her story through Cannabis Science and help our case and education towards general acceptance of medical cannabis as a natural and viable treatment for cancer.
In 1979, Iowa passed a medical marijuana law which impacted five children suffering from cancer and who were placed into a cancer treatment program using medical cannabis under the supervision of the University of Iowa. Dr. Wedewer was one of those children and only 1 1/2 years ago did the law in Iowa finally change to allow these patients to finally speak out about their treatment and success stories in battling cancer with medical cannabis.
The Company is excited to feature Dr. Lynnice Wedewer’s cancer success story and testimonial in its upcoming documentary, along with other cancer survivors who were cured through the use of medical cannabis.
Dr. Wedewer runs a website www.lynnicewedewer.com where she provides her testimony, speeches, educational material, marijuana facts, interviews and documentaries, and other informational links regarding marijuana.
Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, “These are exciting times to be part of a burgeoning medical marijuana movement and shedding light on patients who are telling their stories and opening up medical files to demonstrate the cancer curing power of medical cannabis. We are enthusiastic and hopefully that Dr. Lynnice Wedewer’s testimonial and cancer success along with other patient success stories, including profound medical evidence, will help to educate and finally open up the eyes of federal regulators to decriminalize medical cannabis; so more people’s lives can be saved by this natural herbal remedy and stop killing people with man-made pharmaceuticals."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
The following is in contrast to the research in (inexpensive) cannabinoid extracts as treatment for cancer, and the following does not mention cannabinoids being utilized for research...
"Drugmakers taking a shot at cancer with vaccines"
2014-07-01 by Stephanie M. Lee from the "San Francisco Chronicle" [http://www.sfgate.com/health/article/Drugmakers-taking-a-shot-at-cancer-with-vaccines-5591171.php]:
In the fight against cancer, biopharmaceutical companies are seeing new promise in weapons that could be more powerful and safer than many existing treatments: vaccines.
Cancer vaccines and other emerging cancer immunotherapies make up one of medicine's most active and best-funded areas right now. These treatments, which harness the immune system in various ways to fight or prevent tumors, could generate $35 billion within a decade, analysts say.
Scientists see vaccines as promising because, compared with invasive surgery and toxic chemotherapy, they could prompt the body to attack the disease with impressive results and minimal side effects.
Drugmakers have tried to develop cancer vaccines in the past, but most have failed in clinical trials.
Nonetheless, vaccine makers like Aduro BioTech in Berkeley are forging ahead and earning support from big pharmaceutical companies. In a deal that could be worth up to $365 million, Aduro recently licensed a vaccine for prostate cancer to Janssen Biotech, the pharmaceutical arm of Johnson & Johnson. In a separate agreement, Aduro granted Janssen rights to yet another vaccine technology for prostate cancer. In June, Johnson & Johnson and other investors poured $55 million into privately held Aduro, which has raised $84 million in total.
"We think it's a very promising field, particularly because some of the newer therapeutics, like Aduro's therapeutics, are demonstrating very impressive immune responses," said Dr. Arturo Molina, vice president of oncology scientific innovation at Janssen. "We can characterize the immune responses and see that these are very specific for tumor cells."
Boost prostate therapy -
Johnson & Johnson already has a drug for prostate cancer, Zytiga, and is committed to paying up to $1 billion for Aragon Pharmaceuticals' experimental prostate cancer drugs. But Molina thinks these therapies could be even more powerful against prostate cancer if combined with Aduro's immune treatments.
Johnson & Johnson isn't alone in its enthusiasm for the general field of immuno-oncology. Last year, Citi estimated that such drugs would be a $35 billion market by 2023.
"There is a lot of excitement, and I would say it's sort of unprecedented what's happening in the cancer immunotherapy arena now," said Dr. Lynn Schuchter, an oncologist at the University of Pennsylvania and chair of the cancer research committee for the American Society of Clinical Oncology. "Many people thought it was a dead field, but it is alive."
What is driving the investment, she said, is scientists' increasingly deeper knowledge of how the immune system works.
"In the past, we just targeted things that were sort of a red flag but maybe irrelevant to the actual function of the cancer cell," Schuchter said. "What you're seeing are more approaches that attack the Achilles' heel of a cancer cell or combine different types of immunotherapies with a vaccine."
There are already some well-known vaccines that help prevent cancer, called prophylactic vaccines. Gardasil and Cervarix protect people against the human papilloma virus, which is linked to cervical cancer. Most children are vaccinated against hepatitis B, which can lead to liver cancer.
Vaccines' tricky design -
But scientists have had a trickier time designing therapeutic vaccines, or vaccines that treat existing cancers. Cancer cells often don't "look" dangerous or foreign to the body, so vaccines must be powerful enough to make the immune system attack them. At the same time, vaccines must prompt the immune system to go after specific targets without damaging "good" cells.
Just one cancer treatment vaccine is currently available: Dendreon's Provenge, which is for some men with metastatic prostate cancer.
On the other hand, promising vaccines from Amgen, GlaxoSmithKline, Oncothyreon, Ziopharm and Keryx have all failed to hold up in clinical trials. Other companies have instead pursued different immunotherapies that boost the immune system in general or attack specific parts of cancer cells.
Germ made safe -
One of Aduro's types of vaccines involves Listeria monocytogenes, a germ that's best-known for contaminating food but has been engineered to be safe in humans. Listeria has been shown to activate the immune system, and it also boosts the effectiveness of other vaccines and treatments, Aduro says.
Another type of vaccine involves tumor cell lines that have been irradiated and engineered to prompt the immune system to go after tumor cells.
Aduro is testing its vaccines on several cancers besides prostate cancer, including pancreatic cancer, mesothelioma, glioblastoma and ovarian cancer. Some are being tested in combination with chemotherapy or radiation therapy.
The flu-like symptoms patients have reported so far suggest the treatments are less toxic than chemotherapy or radiation alone, said Stephen Isaacs, Aduro's president and CEO.
"It's a much more holistic way to address the disease - using the power of the body to fight the cancer instead of chemicals," he said.